These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28253833)

  • 21. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
    Babiker HM; Karass M; Recio-Boiles A; Chandana SR; McBride A; Mahadevan D
    Expert Opin Investig Drugs; 2019 Jul; 28(7):583-592. PubMed ID: 31215251
    [No Abstract]   [Full Text] [Related]  

  • 22. The trend toward more target therapy in pancreatic ductal adenocarcinoma.
    Deiana C; Agostini M; Brandi G; Giovannetti E
    Expert Rev Anticancer Ther; 2024 Jul; 24(7):525-565. PubMed ID: 38768098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging protein kinase inhibitors for treating pancreatic cancer.
    Furuse J; Nagashima F
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):77-86. PubMed ID: 28253828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    Christenson ES; Jaffee E; Azad NS
    Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Therapeutics for Pancreatic Adenocarcinoma.
    Lowery MA; O'Reilly EM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.
    Lu Z; Weniger M; Jiang K; Boeck S; Zhang K; Bazhin A; Miao Y; Werner J; D'Haese JG
    Target Oncol; 2018 Aug; 13(4):447-459. PubMed ID: 30062609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging kinase inhibitors of the treatment of gastric cancer.
    Vincenzi B; Imperatori M; Silletta M; Marrucci E; Santini D; Tonini G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):479-93. PubMed ID: 26021342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
    Rubinson DA; Wolpin BM
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    Sahin IH; Iacobuzio-Donahue CA; O'Reilly EM
    Expert Opin Ther Targets; 2016; 20(3):341-59. PubMed ID: 26439702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy.
    Yao HP; Hudson R; Wang MH
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188360. PubMed ID: 32234337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cetuximab: still an option in the treatment of pancreatic cancer?
    Faloppi L; Andrikou K; Cascinu S
    Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.
    Bisht S; Brossart P; Feldmann G
    Oncol Res Treat; 2018; 41(10):590-594. PubMed ID: 30286472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
    Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel systemic treatment approaches for metastatic pancreatic cancer.
    Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
    Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
    Engelhardt K; Riley C; Cooke L; Mahadevan D
    Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead.
    Aslan M; Shahbazi R; Ulubayram K; Ozpolat B
    Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promising new therapies in advanced pancreatic adenocarcinomas.
    Kundranda M; Kachaamy T
    Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.